Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

GLP-1 drugs, such as Wegovy and Ozempic, are gaining popularity in the US and Europe for their appetite-suppressing ...

As the weight-loss drugs become more popular, consumer habits are starting to reflect changing consumption behavior, ...

Achieving and maintaining a healthy weight is beneficial for a number of reasons. A healthy weight lowers a person's chance ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Attorney General Kwame Raoul is warning Illinois residents seeking GLP-1 medications – Ozempic, Wegovy, Mounjaro, Zepbound ...

Purchases of calorie-dense, processed items such as chips, baked goods and cookies were most affected, according to findings ...

The surging popularity of GLP-1 drugs is beginning to obscure the health consequences if people stop taking them, physicians ...

MassHealth is transitioning coverage for anti-obesity drugs, designating Zepbound as the preferred option starting in January 2025, with Wegovy and Saxenda being discontinued for most adult members.

GLP-1 weight-loss drugs are cutting calories… and grocery bills, according to a new study from Cornell and Numerator.

The weight-loss market began feeling some growing pains as the year ended, creating more wariness for the upcoming year. For ...

THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of ...